Novartis India Limited

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUNPHARMA.NS has a market cap of 4.2T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUNPHARMA.NS trades at ₹1,785.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUNPHARMA.NS's P/E ratio is 38.72. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUNPHARMA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUNPHARMA.BO has a market cap of 4.2T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUNPHARMA.BO trades at ₹1,784.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUNPHARMA.BO's P/E ratio is 38.76. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUNPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while DIVISLAB.BO trades at ₹6,470.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas DIVISLAB.BO's P/E ratio is 68.71. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check DIVISLAB.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while DIVISLAB.NS trades at ₹6,474.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas DIVISLAB.NS's P/E ratio is 68.69. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check DIVISLAB.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while TORNTPHARM.BO trades at ₹4,400.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas TORNTPHARM.BO's P/E ratio is 69.88. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check TORNTPHARM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while TORNTPHARM.NS trades at ₹4,399.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas TORNTPHARM.NS's P/E ratio is 65.76. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check TORNTPHARM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while DRREDDY.BO trades at ₹1,318.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas DRREDDY.BO's P/E ratio is 19.26. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check DRREDDY.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while DRREDDY.NS trades at ₹1,319.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas DRREDDY.NS's P/E ratio is 19.25. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check DRREDDY.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while LUPIN.NS trades at ₹2,323.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas LUPIN.NS's P/E ratio is 22.60. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check LUPIN.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while LUPIN.BO trades at ₹2,323.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas LUPIN.BO's P/E ratio is 24.29. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check LUPIN.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ZYDUSLIFE.NS has a market cap of 925.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ZYDUSLIFE.NS trades at ₹938.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ZYDUSLIFE.NS's P/E ratio is 18.76. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ZYDUSLIFE.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ZYDUSLIFE.BO has a market cap of 925.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ZYDUSLIFE.BO trades at ₹938.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ZYDUSLIFE.BO's P/E ratio is 18.75. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ZYDUSLIFE.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, MANKIND.NS has a market cap of 889.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while MANKIND.NS trades at ₹2,279.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas MANKIND.NS's P/E ratio is 49.92. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check MANKIND.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, MANKIND.BO has a market cap of 889.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while MANKIND.BO trades at ₹2,280.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas MANKIND.BO's P/E ratio is 49.92. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check MANKIND.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AUROPHARMA.BO has a market cap of 705.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AUROPHARMA.BO trades at ₹1,222.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AUROPHARMA.BO's P/E ratio is 20.61. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AUROPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AUROPHARMA.NS has a market cap of 703.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AUROPHARMA.NS trades at ₹1,220.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AUROPHARMA.NS's P/E ratio is 20.16. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AUROPHARMA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ALKEM.NS has a market cap of 672.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ALKEM.NS trades at ₹5,752.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ALKEM.NS's P/E ratio is 28.35. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ALKEM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ALKEM.BO has a market cap of 671.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ALKEM.BO trades at ₹5,750.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ALKEM.BO's P/E ratio is 28.31. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ALKEM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GLENMARK.NS has a market cap of 588.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GLENMARK.NS trades at ₹2,124.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GLENMARK.NS's P/E ratio is 55.35. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GLENMARK.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GLENMARK.BO has a market cap of 588.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GLENMARK.BO trades at ₹2,127.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GLENMARK.BO's P/E ratio is 55.24. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GLENMARK.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, LAURUSLABS.NS has a market cap of 581.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while LAURUSLABS.NS trades at ₹1,092.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas LAURUSLABS.NS's P/E ratio is 68.86. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check LAURUSLABS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, LAURUSLABS.BO has a market cap of 580.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while LAURUSLABS.BO trades at ₹1,092.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas LAURUSLABS.BO's P/E ratio is 68.75. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check LAURUSLABS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUVENPHAR.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUVENPHAR.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, IPCALAB.NS has a market cap of 386.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while IPCALAB.NS trades at ₹1,522.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas IPCALAB.NS's P/E ratio is 42.57. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check IPCALAB.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, IPCALAB.BO has a market cap of 386.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while IPCALAB.BO trades at ₹1,522.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas IPCALAB.BO's P/E ratio is 42.48. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check IPCALAB.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AJANTPHARM.BO has a market cap of 377.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AJANTPHARM.BO trades at ₹2,981.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AJANTPHARM.BO's P/E ratio is 37.27. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AJANTPHARM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AJANTPHARM.NS has a market cap of 377.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AJANTPHARM.NS trades at ₹2,978.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AJANTPHARM.NS's P/E ratio is 37.24. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AJANTPHARM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, JBCHEPHARM.BO has a market cap of 334.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while JBCHEPHARM.BO trades at ₹2,082.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas JBCHEPHARM.BO's P/E ratio is 44.03. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check JBCHEPHARM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, JBCHEPHARM.NS has a market cap of 334.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while JBCHEPHARM.NS trades at ₹2,081.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas JBCHEPHARM.NS's P/E ratio is 44.00. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check JBCHEPHARM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, EMCURE.NS has a market cap of 271.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while EMCURE.NS trades at ₹1,454.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas EMCURE.NS's P/E ratio is 31.19. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check EMCURE.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check PEL.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, WOCKPHARMA.NS has a market cap of 223.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while WOCKPHARMA.NS trades at ₹1,363.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas WOCKPHARMA.NS's P/E ratio is 1119.59. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check WOCKPHARMA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, WOCKPHARMA.BO has a market cap of 223.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while WOCKPHARMA.BO trades at ₹1,365.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas WOCKPHARMA.BO's P/E ratio is 1117.36. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check WOCKPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ASTRAZEN.NS has a market cap of 221.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ASTRAZEN.NS trades at ₹8,849.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ASTRAZEN.NS's P/E ratio is 110.85. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ASTRAZEN.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ASTRAZEN.BO has a market cap of 220.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ASTRAZEN.BO trades at ₹8,850.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ASTRAZEN.BO's P/E ratio is 110.08. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ASTRAZEN.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, PPLPHARMA.BO has a market cap of 213B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while PPLPHARMA.BO trades at ₹162.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas PPLPHARMA.BO's P/E ratio is -129.80. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check PPLPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ERIS.BO has a market cap of 188B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ERIS.BO trades at ₹1,361.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ERIS.BO's P/E ratio is 43.83. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ERIS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ERIS.NS has a market cap of 188B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ERIS.NS trades at ₹1,361.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ERIS.NS's P/E ratio is 43.72. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ERIS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, NATCOPHARM.BO has a market cap of 175.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while NATCOPHARM.BO trades at ₹971.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas NATCOPHARM.BO's P/E ratio is 11.39. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check NATCOPHARM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, NATCOPHARM.NS has a market cap of 175.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while NATCOPHARM.NS trades at ₹972.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas NATCOPHARM.NS's P/E ratio is 11.25. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check NATCOPHARM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, NEULANDLAB.NS has a market cap of 171B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while NEULANDLAB.NS trades at ₹13,204.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas NEULANDLAB.NS's P/E ratio is 95.74. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check NEULANDLAB.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, NEULANDLAB.BO has a market cap of 171B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while NEULANDLAB.BO trades at ₹13,211.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas NEULANDLAB.BO's P/E ratio is 95.71. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check NEULANDLAB.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GRANULES.NS has a market cap of 145.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GRANULES.NS trades at ₹591.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GRANULES.NS's P/E ratio is 26.68. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GRANULES.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GRANULES.BO has a market cap of 145.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GRANULES.BO trades at ₹590.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GRANULES.BO's P/E ratio is 26.67. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GRANULES.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, APLLTD.NS has a market cap of 145.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while APLLTD.NS trades at ₹729.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas APLLTD.NS's P/E ratio is 23.06. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check APLLTD.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, APLLTD.BO has a market cap of 145.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while APLLTD.BO trades at ₹728.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas APLLTD.BO's P/E ratio is 23.02. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check APLLTD.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, JUBLPHARMA.NS has a market cap of 142.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while JUBLPHARMA.NS trades at ₹882.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas JUBLPHARMA.NS's P/E ratio is 32.93. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check JUBLPHARMA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, JUBLPHARMA.BO has a market cap of 141.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while JUBLPHARMA.BO trades at ₹881.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas JUBLPHARMA.BO's P/E ratio is 32.80. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check JUBLPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GLS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GLS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, CAPLIPOINT.BO has a market cap of 131.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while CAPLIPOINT.BO trades at ₹1,726.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas CAPLIPOINT.BO's P/E ratio is 21.44. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check CAPLIPOINT.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, CAPLIPOINT.NS has a market cap of 131.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while CAPLIPOINT.NS trades at ₹1,728.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas CAPLIPOINT.NS's P/E ratio is 21.47. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check CAPLIPOINT.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, COHANCE.NS has a market cap of 118.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while COHANCE.NS trades at ₹308.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas COHANCE.NS's P/E ratio is 61.24. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check COHANCE.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, COHANCE.BO has a market cap of 118.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while COHANCE.BO trades at ₹308.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas COHANCE.BO's P/E ratio is 60.99. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check COHANCE.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ALIVUS.NS has a market cap of 111.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ALIVUS.NS trades at ₹920.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ALIVUS.NS's P/E ratio is 20.50. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ALIVUS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ALIVUS.BO has a market cap of 111.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ALIVUS.BO trades at ₹920.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ALIVUS.BO's P/E ratio is 20.51. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ALIVUS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check CAPPL.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, VIYASH.NS has a market cap of 95.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while VIYASH.NS trades at ₹225.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas VIYASH.NS's P/E ratio is 84.66. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check VIYASH.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, PGHL.BO has a market cap of 86.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while PGHL.BO trades at ₹5,128.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas PGHL.BO's P/E ratio is 36.54. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check PGHL.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, PGHL.NS has a market cap of 85.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while PGHL.NS trades at ₹5,124.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas PGHL.NS's P/E ratio is 36.03. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check PGHL.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, STAR.NS has a market cap of 79.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while STAR.NS trades at ₹863.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas STAR.NS's P/E ratio is 15.57. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check STAR.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, STAR.BO has a market cap of 79.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while STAR.BO trades at ₹862.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas STAR.BO's P/E ratio is 15.55. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check STAR.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AKUMS.NS has a market cap of 73.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AKUMS.NS trades at ₹482.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AKUMS.NS's P/E ratio is 22.88. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AKUMS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AARTIPHARM.BO has a market cap of 64.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AARTIPHARM.BO trades at ₹717.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AARTIPHARM.BO's P/E ratio is 30.15. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AARTIPHARM.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AARTIPHARM.NS has a market cap of 64.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AARTIPHARM.NS trades at ₹719.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AARTIPHARM.NS's P/E ratio is 30.06. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AARTIPHARM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SHILPAMED.NS has a market cap of 64B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SHILPAMED.NS trades at ₹339.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SHILPAMED.NS's P/E ratio is 28.93. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SHILPAMED.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, FDC.BO has a market cap of 59.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while FDC.BO trades at ₹364.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas FDC.BO's P/E ratio is 27.53. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check FDC.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, FDC.NS has a market cap of 59.3B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while FDC.NS trades at ₹363.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas FDC.NS's P/E ratio is 27.43. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check FDC.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SEQUENT.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SEQUENT.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SPARC.NS has a market cap of 42.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SPARC.NS trades at ₹128.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SPARC.NS's P/E ratio is -15.87. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SPARC.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SPARC.BO has a market cap of 42.4B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SPARC.BO trades at ₹128.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SPARC.BO's P/E ratio is -15.83. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SPARC.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, INNOVACAP.NS has a market cap of 38.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while INNOVACAP.NS trades at ₹673.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas INNOVACAP.NS's P/E ratio is 28.92. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check INNOVACAP.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GUJTHEM.NS has a market cap of 34.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GUJTHEM.NS trades at ₹313.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GUJTHEM.NS's P/E ratio is 71.89. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GUJTHEM.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUVEN.BO has a market cap of 34.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUVEN.BO trades at ₹148.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUVEN.BO's P/E ratio is -12.18. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUVEN.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SUVEN.NS has a market cap of 34.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SUVEN.NS trades at ₹147.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SUVEN.NS's P/E ratio is -12.16. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SUVEN.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AARTIDRUGS.NS has a market cap of 33.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AARTIDRUGS.NS trades at ₹369.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AARTIDRUGS.NS's P/E ratio is 16.74. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AARTIDRUGS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, AARTIDRUGS.BO has a market cap of 33.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while AARTIDRUGS.BO trades at ₹368.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas AARTIDRUGS.BO's P/E ratio is 16.72. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check AARTIDRUGS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SHILPAMED.BO has a market cap of 32B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SHILPAMED.BO trades at ₹340.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SHILPAMED.BO's P/E ratio is 29.02. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SHILPAMED.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ORCHPHARMA.NS has a market cap of 32B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ORCHPHARMA.NS trades at ₹627.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ORCHPHARMA.NS's P/E ratio is 169.06. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ORCHPHARMA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ORCHPHARMA.BO trades at ₹629.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ORCHPHARMA.BO's P/E ratio is 167.47. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ORCHPHARMA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, RPGLIFE.NS has a market cap of 31.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while RPGLIFE.NS trades at ₹1,909.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas RPGLIFE.NS's P/E ratio is 15.62. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check RPGLIFE.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, RPGLIFE.BO has a market cap of 31.5B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while RPGLIFE.BO trades at ₹1,910.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas RPGLIFE.BO's P/E ratio is 15.55. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check RPGLIFE.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GUFICBIO.BO has a market cap of 28B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GUFICBIO.BO trades at ₹283.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GUFICBIO.BO's P/E ratio is 49.22. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GUFICBIO.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, GUFICBIO.NS has a market cap of 28B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while GUFICBIO.NS trades at ₹282.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas GUFICBIO.NS's P/E ratio is 49.17. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check GUFICBIO.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, UNICHEMLAB.BO has a market cap of 25.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while UNICHEMLAB.BO trades at ₹352.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas UNICHEMLAB.BO's P/E ratio is 8.54. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check UNICHEMLAB.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, UNICHEMLAB.NS has a market cap of 25.1B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while UNICHEMLAB.NS trades at ₹350.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas UNICHEMLAB.NS's P/E ratio is 8.52. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check UNICHEMLAB.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, HIKAL.NS has a market cap of 24.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while HIKAL.NS trades at ₹201.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas HIKAL.NS's P/E ratio is -189.52. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to HIKAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check HIKAL.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, HIKAL.BO has a market cap of 24.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while HIKAL.BO trades at ₹202.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas HIKAL.BO's P/E ratio is 251.06. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check HIKAL.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, MOREPENLAB.NS has a market cap of 24.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while MOREPENLAB.NS trades at ₹44.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas MOREPENLAB.NS's P/E ratio is 24.54. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check MOREPENLAB.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, MOREPENLAB.BO has a market cap of 24.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while MOREPENLAB.BO trades at ₹44.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas MOREPENLAB.BO's P/E ratio is 24.66. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check MOREPENLAB.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, ALEMBICLTD.NS has a market cap of 23.6B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while ALEMBICLTD.NS trades at ₹91.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas ALEMBICLTD.NS's P/E ratio is 7.30. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check ALEMBICLTD.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, BLISSGVS.BO has a market cap of 23.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while BLISSGVS.BO trades at ₹217.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas BLISSGVS.BO's P/E ratio is 21.52. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check BLISSGVS.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, BLISSGVS.NS has a market cap of 23.2B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while BLISSGVS.NS trades at ₹217.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas BLISSGVS.NS's P/E ratio is 21.54. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check BLISSGVS.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SOLARA.NS has a market cap of 22.8B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SOLARA.NS trades at ₹463.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SOLARA.NS's P/E ratio is -98.27. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, NOVARTIND.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SOLARA.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, SOLARA.BO has a market cap of 22.7B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while SOLARA.BO trades at ₹463.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas SOLARA.BO's P/E ratio is -97.91. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check SOLARA.BO's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, IOLCP.NS has a market cap of 21.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while IOLCP.NS trades at ₹74.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas IOLCP.NS's P/E ratio is 18.93. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check IOLCP.NS's competition here

NOVARTIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVARTIND.BO stands at 23.1B. In comparison, IOLCP.BO has a market cap of 21.9B. Regarding current trading prices, NOVARTIND.BO is priced at ₹924.35, while IOLCP.BO trades at ₹73.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVARTIND.BO currently has a P/E ratio of 23.76, whereas IOLCP.BO's P/E ratio is 18.92. In terms of profitability, NOVARTIND.BO's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, NOVARTIND.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.BO.Check IOLCP.BO's competition here